- Denosumab effectively increases bone mineral density (BMD) in patients with systemic lupus erythematosus (SLE), but treatment response varies based on disease activity, hydroxychloroquine use, and baseline BMD.
- Higher disease activity (SLEDAI-2K), hydroxychloroquine use, prior osteoporosis treatments, and higher baseline BMD were associated with reduced BMD improvement, while higher body mass index (BMI) and elevated c-telopeptide levels correlated with better outcomes.
- Researchers emphasized the importance of individualized treatment strategies for denosumab therapy in SLE patients, suggesting that tailoring treatment based on baseline BMD and disease factors could enhance therapeutic outcomes.
Factors Influencing Denosumab Efficacy in SLE Osteoporosis Identified
Conexiant
February 5, 2025
